Sjogren's syndrome Musculoskeletal Diseases Other systemic involvement of connective tissue
Conditions
Interventions
Use of an omega-3 supplement (TheraTears Nutrition, Advanced Vision Research, USA) containing 750 mg of long-chain omega-3s (450 mg of eicosapentaenoic acid [EPA] and 300 mg of docosahexaenoic acid [D
Sponsors
Advanced Vision Research (USA)
Eligibility
Inclusion criteria
Inclusion criteria: Subjects with Sjogren's syndrome as defined by the European Criteria and a positive blood test or lip biopsy
Exclusion criteria
Exclusion criteria: 1. Had less than 10 teeth 2. Received periodontal therapy in the past 12 months or antibiotic therapy in the past 1 month 3. Required pre-medication with antibiotics 4. Had advanced periodontitis, an infectious or wasting disease 5. Already supplementing with omega-3s 6. Participating in another clinical trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Increased oral and ocular comfort at 3 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Increased salivary flow and improvement in gingival index (GI) at 3 months | — |
Countries
United States of America
Outcome results
None listed